{"schema_version":"secwatch.filing_event.v1","accession":"0001823239-24-000093","form_type":"8-K","ticker":"MRVI","cik":"0001823239","company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.687772+00:00","generated_at":"2026-05-31T11:52:39.028257+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Maravai Q2 revenue up 6.5% to $73.4M, net loss $14.5M; reaffirms FY2024 guidance","bullets":["Q2 revenue $73.4M (+6.5% YoY); Nucleic Acid Production +9.8%, Biologics Safety Testing -4.7%.","Net loss $(14.5)M vs $(11.9)M prior year; Adjusted EBITDA $16.9M up from $9.1M.","H1 2024 revenue $137.6M (-7% YoY); net loss $(37.2)M vs $(13.3)M.","Reaffirms FY2024 revenue guidance $265M-$285M.","Business updates: TriLink-Johns Hopkins collaboration, Flanders facilities milestones, new product launches."],"urls":{"canonical":"https://secwatch.observer/filing/0001823239-24-000093","json":"https://secwatch.observer/filing/0001823239-24-000093.json","markdown":"https://secwatch.observer/filing/0001823239-24-000093.md","text":"https://secwatch.observer/filing/0001823239-24-000093.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1823239/000182323924000093/0001823239-24-000093-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1823239/000182323924000093/mrvi-20240807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:52:39.028257+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}